Compare e l f Beauty Inc (ELF) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Natera Inc. Common Stock — how do they compare? e l f Beauty Inc trades at $107.55 (market cap $6.38B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.9× e l f Beauty Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 26 Days and Natera Inc. Common Stock for 0 Days on average.
| ELF | NTRA | |
|---|---|---|
Market Cap | $6.38B | $57.03B |
Volume | 856,198 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $136.92 | $425.64 |
52-Week Low | $49.57 | $179.42 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $6.97B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum showing bullish moving averages but overbought RSI readings. The company demonstrates robust revenue growth with Q2 2026 earnings beating expectations by 145%, though valuation metrics remain elevated with a P/E of 110.37. Recent expansion includes rhode brand launches in 19 European markets via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album.
Outlook remains positive with analyst consensus leaning bullish (48% buy ratings) despite premium valuation. Key opportunities include international expansion and market share gains, while risks center on margin compression and competitive pressures in the beauty sector. The stock trades above consensus price target of $95.91, suggesting near-term consolidation potential.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
